TRANSACTION IN OWN SECURITIES
TRANSACTION IN OWN SECURITIES
The Board of Foresight VCT plc (“the Company”) announces that on 22 June 2018 the Company purchased for cancellation 225,000 ordinary shares of 1p at a gross price of 68.5p per share.
In accordance with the FCA's Disclosure and Transparency Rules sourcebook transitional provision 6, Foresight VCT plc advises that, following this purchase, its capital consists of 176,280,430 ordinary shares of 1p with 176,280,430 voting rights attached.
Foresight VCT plc does not hold any shares in Treasury.
Therefore the total number of voting rights in the Company's shares is 176,280,430 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Foresight VCT plc under the FCA's Disclosure and Transparency Rules.
The Company was satisfied that all inside information which the Directors and the Company were previously in receipt of had become publically available prior to the market purchase being completed. Therefore, the Company was not prohibited from dealing in its own securities.
For further information please contact:
Gary Fraser, Foresight Group: 0203 667 8159
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
